0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Viewpoint |

Avoiding Nocebo Effects to Optimize Treatment Outcome

Ulrike Bingel, MD, PhD1; For the Placebo Competence Team
[+] Author Affiliations
1Department of Neurology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
JAMA. 2014;312(7):693-694. doi:10.1001/jama.2014.8342.
Text Size: A A A
Published online

Extract

Converging evidence suggests that the occurrence of unwanted adverse events during drug treatment is in part determined by nonpharmacological effects. For instance, the majority of unwanted adverse effects and symptoms reported by patients in clinical trials often are not caused by the medication, because unwanted adverse effects can also occur to a comparable degree in the placebo group of the study.1 Similarly, the switch from brand name to generic drugs with identical compounds is frequently associated with an increase in unwanted adverse effects and therefore could lead to treatment discontinuation. These examples highlight that patients’ expectations regarding adverse effects are important determinants of unwanted adverse effects during drug treatment.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 2

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Nocebo effects and psychotropic drug action. Expert Rev Clin Pharmacol Published online Dec 12, 2014.;
Jobs
JAMAevidence.com

Users' Guides to the Medical Literature
What are the Results of the Study?

Users' Guides to the Medical Literature
What Are the Results?

brightcove.createExperiences();